AN2 Therapeutics (ANTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on AN2 Therapeutics (ANTX) is Neutral.

The composite score behind that read is +0.03, weighing +0.32 of bullish evidence against -0.37 bearish.

AN2 Therapeutics last closed at $4.30, -2.27% on the session.

Against the IVW growth benchmark the position is -1.84% over the forecast window.

The read is built from 11 underlying insights — 5 bullish and 6 bearish.

Agreement across those insights is 55%.

AN2 Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks AN2 Therapeutics in the 17th percentile on return on equity, where 100 is best.

AN2 Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $166.04M.

StockMap tracks AN2 Therapeutics as the 94th largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 101 Neutral and 51 Moderate Underperform.

On that composite AN2 Therapeutics ranks 10th of 152 in the group, against a group median of -0.13.